Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H/T315I compound mutation: a case report. (PubMed, Front Oncol) - Sep 5, 2026 - "Rather, it provides a cautious, hypothesis-generating clinical observation suggesting possible short-term activity of dual ATP-site and allosteric inhibition in a highly resistant setting. This case also highlights the potential value of long-read sequencing-based mutation profiling with phasing in advanced-phase CML, where distinguishing true compound mutations from separate subclones may be clinically relevant."
Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Pancreatitis • Transplantation • ABL1
|
|
Hongbing Ma; Xu He; Yingying Hu
|